Avodart Related Published Studies
Well-designed clinical trials related to Avodart (Dutasteride)
Preliminary evaluation of the effect of dutasteride on PCA3 in post-DRE urine sediments: a randomized, open-label, parallel-group pilot study. [2009.11.01]
The Effect of Dutasteride on the Efficacy of Photoselective Vaporization of the Prostate: Results of a Randomized, Placebo-controlled, Double-blind Study (DOP Trial). [2009.10.01]
[Assessment of recommended dose of dutasteride on Japanese men with benign prostatic hyperplasia: a randomized, double-blind, placebo-controlled, parallel-group, dose response study] [2009.04]
Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial. [2009.04]
Can dutasteride delay or prevent the progression of prostate cancer in patients with biochemical failure after radical therapy? Rationale and design of the Avodart after Radical Therapy for Prostate Cancer Study. [2009.03]
Efficacy and safety of dutasteride, tamsulosin and their combination in a subpopulation of the CombAT study: 2-year results in Asian men with moderate-to-severe BPH. [2009]
The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride. [2008.07]
The effect of 5alpha-reductase inhibition with dutasteride and finasteride on bone mineral density, serum lipoproteins, hemoglobin, prostate specific antigen and sexual function in healthy young men. [2008.06]
The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. [2008.02]
The effect of 5alpha-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men. [2007.05]
The effect of dutasteride on the peripheral and transition zones of the prostate and the value of the transition zone index in predicting treatment response. [2007.04]
Dutasteride improves male pattern hair loss in a randomized study in identical twins. [2007.03]
The Effect of 5{alpha}-Reductase Inhibition with Dutasteride and Finasteride on Semen Parameters and Serum Hormones in Healthy Men. [2007.02.13]
The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia. [2007]
The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. [2006.12]
The effects of the dual 5alpha-reductase inhibitor dutasteride on localized prostate cancer--results from a 4-month pre-radical prostatectomy study. [2006.11.01]
Dutasteride improves objective and subjective disease measures in men with benign prostatic hyperplasia and modest or severe prostate enlargement. [2006.09]
Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride. [2006.05]
Relationship among serum testosterone, sexual function, and response to treatment in men receiving dutasteride for benign prostatic hyperplasia. [2006.04]
Long-term therapy with the dual 5alpha-reductase inhibitor dutasteride is well tolerated in men with symptomatic benign prostatic hyperplasia. [2006.01]
Three months' treatment with the alpha1-blocker alfuzosin does not affect total or transition zone volume of the prostate. [2006]
Oral testosterone in oil plus dutasteride in men: a pharmacokinetic study. [2005.05]
The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate. [2005.01]
Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. [2004.10]
Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. [2004.10]
Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer. [2004.09]
Dutasteride: a potent dual inhibitor of 5-alpha-reductase for benign prostatic hyperplasia. [2004.08]
Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. [2004.05]
Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. [2004.04]
Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride. [2003.10]
Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor. [2003.08]
Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. [2002.09]
The pharmacokinetic modelling of GI198745 (dutasteride), a compound with parallel linear and nonlinear elimination. [1999.01]
Well-designed clinical trials possibly related to Avodart (Dutasteride)
Effect of discontinuation of 5alpha-reductase inhibitors on prostate volume and symptoms in men with BPH: a prospective study. [2009.04]
Aromatase and 5alpha-reductase inhibition during an exogenous testosterone clamp unveils selective sex steroid modulation of somatostatin and growth hormone secretagogue actions in healthy older men. [2009.03]
Therapeutic effects of add-on botulinum toxin A on patients with large benign prostatic hyperplasia and unsatisfactory response to combined medical therapy. [2009]
Effects of testosterone and levonorgestrel combined with a 5alpha-reductase inhibitor or gonadotropin-releasing hormone antagonist on spermatogenesis and intratesticular steroid levels in normal men. [2005.10]
Novel male hormonal contraceptive combinations: the hormonal and spermatogenic effects of testosterone and levonorgestrel combined with a 5alpha-reductase inhibitor or gonadotropin-releasing hormone antagonist. [2005.01]
The role of 5-alpha-reductase inhibition as monotherapy in view of the MTOPS data. [2004.08]
Validation of a population pharmacokinetic/pharmacodynamic model for 5 alpha-reductase inhibitors. [1999.08]
A model for the turnover of dihydrotestosterone in the presence of the irreversible 5 alpha-reductase inhibitors GI198745 and finasteride. [1998.12]
Other research related to Avodart (Dutasteride)
Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design. [2009.10]
Effect of the dual 5alpha-reductase inhibitor, dutasteride, on serum testosterone and body mass index in men with benign prostatic hyperplasia. [2009.09.29]
The Effects of Combination Therapy with Dutasteride and Tamsulosin on Clinical Outcomes in Men with Symptomatic Benign Prostatic Hyperplasia: 4-Year Results from the CombAT Study. [2009.09.19]
Efficacy and safety of dutasteride in Japanese men with benign prostatic hyperplasia. [2009.09]
Effects of short-term dutasteride and Serenoa repens on perioperative bleeding and microvessel density in patients undergoing transurethral resection of the prostate. [2009.08.09]
Effect of short-term dutasteride therapy on prostate vascularity in patients with benign prostatic hyperplasia: a pilot study. [2009.06]
Biodegradable braided poly(lactic-co-glycolic acid) urethral stent combined with dutasteride in the treatment of acute urinary retention due to benign prostatic enlargement: a pilot study. [2009.03]
Phase II study of Dutasteride for recurrent prostate cancer during androgen deprivation therapy. [2009.02]
The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study. [2009.02]
The Influence of Baseline Parameters on Changes in International Prostate Symptom Score with Dutasteride, Tamsulosin, and Combination Therapy among Men with Symptomatic Benign Prostatic Hyperplasia and an Enlarged Prostate: 2-Year Data from the CombAT Study. [2008.11.06]
Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer. [2008.10]
Effects of testosterone undecanoate administered alone or in combination with letrozole or dutasteride in female to male transsexuals. [2008.10]
Efficacy and safety of dutasteride, tamsulosin and their combination in a subpopulation of the CombAT study: 2-year results in Asian men with moderate-to-severe BPH. [2008.09.23]
Effects of Testosterone Undecanoate Administered Alone or in Combination with Letrozole or Dutasteride in Female to Male Transsexuals. [2008.07.01]
Effects of dutasteride on prostate carcinoma primary cultures: a comparative study with finasteride and MK386. [2008.07]
[Dutasteride in the treatment of hormone refractory prostate cancer] [2008.06]
Pharmacokinetics and pharmacodynamics of oral testosterone enanthate plus dutasteride for 4 weeks in normal men: implications for male hormonal contraception. [2008.05]
Cost comparison of finasteride and dutasteride for enlarged prostate in a managed care setting among Medicare-aged men. [2008.05]
Dutasteride vs finasteride: assessment of differences in acute urinary retention rates and surgical risk outcomes in an elderly population aged > or =65 years. [2008.05]
Nanomilled oral testosterone plus dutasteride effectively normalizes serum testosterone in normal men with induced hypogonadism. [2008.03]
Dutasteride prior to contrast-enhanced colour Doppler ultrasound prostate biopsy increases prostate cancer detection. [2008.01]
Dutasteride significantly improves quality of life measures in patients with enlarged prostate. [2008]
Peginterferon-alpha-2a (40 kD) Plus Ribavirin: A Review of its Use in the Management of Chronic Hepatitis C Mono-Infection. [2008]
The Effects of Dutasteride, Tamsulosin and Combination Therapy on Lower Urinary Tract Symptoms in Men With Benign Prostatic Hyperplasia and Prostatic Enlargement: 2-Year Results From the CombAT Study. [2007.12.12]
Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart(R) and Tamsulosin) trial rationale and study design. [2007.11]
Delay in the progression of low-risk prostate cancer: Rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial. [2007.11]
Dutasteride significantly improves quality of life measures in patients with enlarged prostate. [2007.06.26]
Delay in the progression of low-risk prostate cancer: Rationale and design of the reduction by dutasteride of clinical progression events in expectant management (redeem) trial. [2007.05.29]
Blood loss and postoperative complications associated with transurethral resection of the prostate after pretreatment with dutasteride. [2007.03]
Finasteride versus dutasteride: a real-world economic evaluation. [2007.02]
A large retrospective analysis of acute urinary retention and prostate-related surgery in BPH patients treated with 5-alpha reductase inhibitors: dutasteride versus finasteride. [2007.02]
Finasteride to evaluate the efficacy of dutasteride in the management of patients with lower urinary tract symptoms and enlarged prostate. [2007.01]
Update on the use of dutasteride in the management of benign prostatic hypertrophy. [2007]
The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia. [2006.12.26]
Efficacy of neoadjuvant bicalutamide and dutasteride as a cytoreductive regimen before prostate brachytherapy. [2006.07]
Effect of dutasteride on the symptoms of benign prostatic hyperplasia, and patient quality of life and discomfort, in clinical practice. [2006.07]
Dutasteride: a dual 5-alpha reductase inhibitor for the treatment of symptomatic benign prostatic hyperplasia. [2006.04]
Development of nomogram to predict acute urinary retention or surgical intervention, with or without dutasteride therapy, in men with benign prostatic hyperplasia. [2006.01]
Oral testosterone in oil: pharmacokinetic effects of 5alpha reduction by finasteride or dutasteride and food intake in men. [2006.01]
Discovery and clinical development of dutasteride, a potent dual 5alpha-reductase inhibitor. [2006]
[Effect of dutasteride on reduction of plasma DHT following finasteride therapy in patients with benign prostatic hyperplasia] [2005.12]
[Effect of dutasteride on reduction of intraoperative bleeding related to transurethral resection of the prostate] [2005.12]
Effect of dutasteride therapy on Doppler US evaluation of prostate: preliminary results. [2005.10]
Effective treatment of female androgenic alopecia with dutasteride. [2005.09]
Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5alpha-reductase inhibitor dutasteride: results of 4-year studies. [2005.09]
[Dutasteride (Avodart): a novel 5-alpha reductase inhibitor for treatment of benign prostate hypertrophy] [2005.03]
Dutasteride: a novel dual inhibitor of 5alpha-reductase for benign prostatic hyperplasia. [2005.02]
Chemoprevention using dutasteride: the REDUCE trial. [2005.01]
[Dutasteride: main results in the treatment of benign prostatic hyperplasia] [2004.12]
Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. [2004.09]
Dutasteride: a new 5-alpha reductase inhibitor for men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. [2003.10]
Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. [2003.07]
Dutasteride. [2003]
Other possibly related research studies
Evaluation and medical management of benign prostatic hyperplasia. [2005.10]
[Prevention of prostate cancer] [2005.09.09]
Noninvasive management of lower urinary tract symptoms and sexual dysfunction associated with benign prostatic hyperplasia in the primary care setting. [2005.09]
Selecting therapy for maintaining sexual function in patients with benign prostatic hyperplasia. [2005.08]
[Use of 5-alpha-reductase inhibitors in the prevention of prostate cancer] [2004.12]
ELICITING PREFERENCES FOR DRUG TREATMENT OF LOWER URINARY TRACT SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA. [2004.12]
An update on the use of 5alpha-reductase inhibitors. [2004.03]
|
